| [1] |
Figueiredo V P, Barbosa M A, de Castro U G M, et al. Antioxidant effects of oral ang-(1-7) restore insulin pathway and RAS components ameliorating cardiometabolic disturbances in rats[J]. Oxid Med Cell Longev, 2019, 2019: 5868935.
|
| [2] |
South A M, Shaltout H A, Washburn L K, et al. Fetal programming and the angiotensin-(1-7) axis: a review of the experimental and clinical data[J]. Clin Sci (Lond), 2019, 133(1): 55-74.
|
| [3] |
Rasha F, Ramalingam L, Gollahon L, et al. Mechanisms linking the renin-angiotensin system, obesity, and breast cancer[J]. Endocr Relat Cancer, 2019, 26(12): R653-R672.
|
| [4] |
Marangoci N, Timpu D, Corciova A, et al. Beta-cyclodextrin as a functional excipient used for enhancing the diminazene aceturate bioavailability[J]. Pharmaceutics, 2019, 11(6): 补充起止页码
|
| [5] |
Joviano-Santos J V, Santos-Miranda A, Joca H C, et al. Diminazene aceturate (DIZE) has cellular and in vivo antiarrhythmic effects[J]. Clin Exp Pharmacol Physiol, 2020, 47(2): 213-219.
|
| [6] |
De Maria M L, Araujo L D, Fraga-Silva R A, et al. Anti-hypertensive effects of diminazene aceturate: an angiotensin- converting enzyme 2 activator in rats[J]. Protein Pept Lett, 2016, 23(1): 9-16.
|
| [7] |
Shenoy V, Gjymishka A, Jarajapu Y P, et al. Diminazene attenuates pulmonary hypertension and improves angiogenic progenitor cell functions in experimental models[J]. Am J Respir Crit Care Med, 2013, 187(6): 648-657.
|
| [8] |
Bessa A S M, Jesus E F, Nunes A D C, et al. Stimulation of the ACE2/Ang-(1-7)/Mas axis in hypertensive pregnant rats attenuates cardiovascular dysfunction in adult male offspring[J]. Hypertens Res, 2019, 42(12): 1883-1893.
|
| [9] |
Macedo L M, Souza A P, De Maria M L, et al. Cardioprotective effects of diminazene aceturate in pressure-overloaded rat hearts[J]. Life Sci, 2016, 155: 63-69.
|
| [10] |
Rabelo L A, Todiras M, Nunes-Souza V, et al. Genetic deletion of ACE2 induces vascular dysfunction in c57bl/6 mice: role of nitric oxide imbalance and oxidative stress[J]. PLoS One, 2016, 11(4): e0150255.
|
| [11] |
Raffai G, Khang G, Vanhoutte P M. Angiotensin-(1-7) augments endothelium-dependent relaxations of porcine coronary arteries to bradykinin by inhibiting angiotensin-converting enzyme 1[J]. J Cardiovasc Pharmacol, 2014, 63(5): 453-460.
|
| [12] |
Castardeli C, Sartorio C L, Pimentel E B, et al. The ACE 2 activator diminazene aceturate (DIZE) improves left ventricular diastolic dysfunction following myocardial infarction in rats[J]. Biomed Pharmacother, 2018, 107: 212-218.
|
| [13] |
Goru S K, Kadakol A, Malek V, et al. Diminazene aceturate prevents nephropathy by increasing glomerular ACE2 and AT2 receptor expression in a rat model of type1 diabetes[J]. Br J Pharmacol, 2017, 174(18): 3118-3130.
|
| [14] |
Sharma N, Malek V, Mulay S R, et al. Angiotensin II type 2 receptor and angiotensin-converting enzyme 2 mediate ischemic renal injury in diabetic and non-diabetic rats[J]. Life Sci, 2019, 235: 116796.
|
| [15] |
Malek V, Sharma N, Sankrityayan H, et al. Concurrent neprilysin inhibition and renin-angiotensin system modulations prevented diabetic nephropathy[J]. Life Sci, 2019, 221(3): 159-167.
|
| [16] |
Malek M, Nematbakhsh M. The preventive effects of diminazene aceturate in renal ischemia/reperfusion injury in male and female rats[J]. Adv Prev Med, 2014, 2014: 740647.
|
| [17] |
Kangussu L M, de Almeida T C S, Prestes T R R, et al. Beneficial effects of the angiotensin-converting enzyme 2 activator dize in renovascular hypertension[J]. Protein Pept Lett, 2019, 26(7): 523-531.
|
| [18] |
Huskova Z, Kopkan L, Cervenkova L, et al. Intrarenal alterations of the angiotensin-converting enzyme type 2/angiotensin 1-7 complex of the renin-angiotensin system do not alter the course of malignant hypertension in Cyp1a1-Ren-2 transgenic rats[J]. Clin Exp Pharmacol Physiol, 2016, 43(4): 438-449.
|
| [19] |
Pei N, Mao Y, Wan P, et al. Angiotensin II type 2 receptor promotes apoptosis and inhibits angiogenesis in bladder cancer[J]. J Exp Clin Cancer Res, 2017, 36(1): 77.
|
| [20] |
Yu X, Cui L, Hou F, et al. Angiotensin-converting enzyme 2-angiotensin (1-7)-Mas axis prevents pancreatic acinar cell inflammatory response via inhibition of the p38 mitogen-activated protein kinase/nuclear factor-kappaB pathway[J]. Int J Mol Med, 2018, 41(1): 409-420.
|
| [21] |
Murphy K T, Hossain M I, Swiderski K, et al. Mas receptor activation slows tumor growth and attenuates muscle wasting in cancer[J]. Cancer Res, 2019, 79(4): 706-719.
|
| [22] |
Gegotek A, Cyunczyk M, Luczaj W, et al. The redox status of human breast cancer cell lines (MCF-7 and MDA-MB231) treated with novel dinuclear berenil-platinum(II) complexes[J]. Pharmazie, 2014, 69(12): 923-928.
|
| [23] |
Zhang Q, Lu S, Li T, et al. ACE2 inhibits breast cancer angiogenesis via suppressing the VEGFa/VEGFR2/ERK pathway[J]. J Exp Clin Cancer Res, 2019, 38(1): 173.
|
| [24] |
Mikek C G, West S J, Gwin J C, et al. Berenil binds tightly to parallel and mixed parallel/antiparallel g-quadruplex motifs with varied thermodynamic signatures[J]. ACS Omega, 2018, 3(9): 11582-11591.
|
| [25] |
Wang C, Carter-Cooper B, Du Y, et al. Alkyne-substituted diminazene as G-quadruplex binders with anticancer activities[J]. Eur J Med Chem, 2016, 118(8): 266-275.
|
| [26] |
Ge P, Yao X, Li J, et al. Diminazene aceturate alleviated lipopolysaccharide/D-galactosamine-induced fulminant hepatitis in mice[J]. Biomed Pharmacother, 2018, 98(2): 142-148.
|
| [27] |
Dhawale V S, Amara V R, Karpe P A, et al. Activation of angiotensin-converting enzyme 2 (ACE2) attenuates allergic airway inflammation in rat asthma model[J]. Toxicol Appl Pharmacol, 2016, 306(9): 17-26.
|
| [28] |
Zheng C, Lei C, Chen Z, et al. Topical administration of diminazene aceturate decreases inflammation in endotoxin-induced uveitis[J]. Mol Vis, 2015, 21(4): 403-411.
|
| [29] |
Queiroz-Junior C M, Santos A C P M, Galvão I, et al. The angiotensin converting enzyme 2/angiotensin-(1-7)/Mas Receptor axis as a key player in alveolar bone remodeling[J].Bone, 2019, 128(11): 115041.
|
|
|
2021, Vol. 32 
